Oasmia Pharmaceutical

Oasmia Pharmaceutical announces poster presentation at American Society of Clinical Oncology 2020 annual meeting | 5/14/2020

Oasmia Pharmaceutical announces poster presentation at American Society of Clinical Oncology 2020 annual meeting Posted May 14th, 2020 for Oasmia Uppsala, Sweden, May 14, 2020 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, announces that data collected from the Company’s development program of docecal, a solvent-free nanoparticle micellar formulation of docetaxel have been accepted for a poster presentation at the American Society of Clinical Oncology (ASCO) 2020 Annual …

Oasmia announces outcome of strategic review to deliver long-term, profitable growth as a specialty pharma company | 5/13/2020

Print Uppsala, Sweden, May 13, 2020. Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, today announced the outcome of a strategic review assessing all aspects of the business to maximise the company’s resources, to achieve the full potential of its XR17 platform technology and to optimise Oasmia’s path towards long-term, profitable growth. The review was undertaken by Oasmia following the appointment of Francois Martelet as Chief Executive Officer …

Follow Oasmia Pharmaceutical:    

Elevar Therapeutics Acquires Global Rights to European Approved Apealea® from Oasmia Pharmaceutical | PR Newswire | 3/25/2020

SALT LAKE CITY , March 25, Elevar Therapeutics, Inc., a fast-growing biopharmaceutical company focused on promising therapies for unmet medical needs in cancer, announced today an agreement with Swedish-based Oasmia Pharmaceutical AP to obtain global rights for Apealea®, except in Nordics, Russia , and certain countries in Eastern Europe. Apealea® is a non-cremophor formulation of the well-known chemotherapeutic agent paclitaxel. It has been approved by the European regulatory …

Financial Survey: OASMIA PHARMACE/ADR (NASDAQ:OASM) and AgeX Therapeutics (NASDAQ:AGE) | 2/25/2020

… the treatment of prostate, lung, and breast cancer; OAS-19, a cancer drug; and KB9520 to treat various types of cancer. The company also develops Doxophos Vet, a formulation to treat lymphoma in dogs. Oasmia Pharmaceutical AB (publ) was founded in 1990 and is based in Uppsala, Sweden. AgeX Therapeutics Company Profile AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative …

Global Pet Cancer Therapeutics Market Research Report 2020 | 2/7/2020

… Area Served 6.9.2 Regeneus Ltd. Description, Business Overview and Total Revenue 6.9.3 Regeneus Ltd. Pet Cancer Therapeutics Sales, Revenue and Gross Margin (2015-2020) 6.9.4 Regeneus Ltd. Products Offered 6.9.5 Regeneus Ltd. Recent Development 6.10 Oasmia Pharmaceutical s AB 6.10.1 Oasmia Pharmaceutical s AB Pet Cancer Therapeutics Production Sites and Area Served 6.10.2 Oasmia Pharmaceutical s AB Description, Business Overview and Total Revenue 6.10.3 Oasmia Pharmaceutical s AB Pet Cancer Therapeutics Sales, Revenue and Gross …

Oasmia to present at Biotech Showcase in San Francisco | 1/10/2020

Oasmia Pharmaceutical AB has been selected to present at the Biotech Showcase Conference and will be presenting its technology on Tuesday 14 January at 15:30 (3:30 pm), Track Yosemite C (Ballroom level). Biotech Showcase Conference, January 13–15, 2020, is one of the industry’s leading industry and investor conferences expecting more than 3,700 attendees, 2,200 companies, and over 1,000 investors. The conference, produced by Demy-Colton and EBD Group, is …

Oasmia resolves on a rights issue of approximately SEK 399 million Stockholm Stock Exchange:OASM | Globe Newswire | 11/11/2019

… release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Oasmia Pharmaceuticals AB (publ). See the section “IMPORTANT INFORMATION” below. The Board of Directors of Oasmia Pharmaceutical AB (publ) (”Oasmia” or the “Company”) has, by virtue of an authorization from the extraordinary general meeting on 6 November 2019, resolved to carry out a new issue of shares with preferential rights for …

Oasmia recruits Michael of Winklerfelt as new CFO | Globe Newswire | 10/30/2019

October 30, 2019 02:15 ET Source: Oasmia Pharmaceutical AB multilang-release Michael af Winklerfelt has been appointed as new CFO of Oasmia Pharmaceutical AB. He will be a member of the management team and will take up his position on November 4. Michael af Winklerfelt is 47 years old and was most recently with a British venture capital company, where in recent years he has worked with financial control as …

The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million | Globe Newswire | 10/14/2019

October 14, 2019 14:46 ET Source: Oasmia Pharmaceutical AB multilang-release The Board of Directors in Oasmia Pharmaceutical AB (”Oasmia” or the ”Company”) today announces a notice to an extra general meeting on 6 November 2019. It is proposed that the extra general meeting resolves to authorise the Board of Directors to carry out a rights issue of approximately SEK 400 million (the “Rights Issue”). The proceeds from the Rights …

The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million Stockholm Stock Exchange:OASM | Globe Newswire | 10/14/2019

The Board of Directors in Oasmia Pharmaceutical AB (”Oasmia” or the ”Company”) today announces a notice to an extra general meeting on 6 November 2019. It is proposed that the extra general meeting resolves to authorise the Board of Directors to carry out a rights issue of approximately SEK 400 million (the “Rights Issue”). The proceeds from the Rights Issue will primarily be used to finance and accelerate the commercialization …

DEADLINE ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action and Lead Plaintiff Deadline: September 27, 2019 | Globe Newswire | 9/27/2019

September 27, 2019 15:00 ET Source: Bronstein, Gewirtz & Grossman, LLC NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) – Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Oasmia securities between October 23, 2015 through July 9, 2019, both dates inclusive …

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2019 – Company Announcement - FT.com | Financial Times | 9/26/2019

… this stage. A great team effort! Sven Rohmann, interim CEO of Oasmia For more information: Urban Ekelund Investor Relations Oasmia Phone: +46 18-50 54 40 E-mail: [email protected] This information is information that Oasmia Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 07:30 CET on …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Oasmia Pharmaceutical AB | Globe Newswire | 9/23/2019

September 23, 2019 11:00 ET Source: Glancy Prongay & Murray LLP LOS ANGELES, Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 27, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM ) investors who purchased securities between October 23, 2015 and July 9, 2019 , inclusive (the “Class Period”). If you are a shareholder …

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Oasmia Pharmaceutical AB | Globe Newswire | 9/20/2019

September 20, 2019 11:00 ET Source: Law Offices of Howard G. Smith BENSALEM, Pa., Sept. 20, Law Offices of Howard G. Smith reminds investors of the upcoming September 27, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM ) securities between October 23, 2015 and July 9, 2019 , inclusive (the “Class Period …

7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | Globe Newswire | 9/20/2019

September 20, 2019 11:05 ET Source: Schall Law LOS ANGELES, Sept. 20, 2019 (GLOBE NEWSWIRE) – The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Oasmia Pharmaceutical AB (“Oasmia” or “the Company”) (NASDAQ: OASM ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange …

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Oasmia Pharmaceutical AB (NASDAQ: OASM) and Encourages Oasmia Investors to Contact the Firm | PR Newswire | 9/19/2019

NEW YORK Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of all investors that purchased Oasmia Pharmaceutical AB (NASDAQ: OASM ) securities between October 23, 2015 and July 9, 2019 (the “Class Period”). Investors have until September 27 , 2019 to apply to the Court to be appointed as lead plaintiff …

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Oasmia Pharmaceutical AB (NASDAQ: OASM) and Encourages Oasmia Investors to Contact … | Markets Insider | Business Insider | 9/18/2019

NEW YORK , Sept. 18, 2019 /PRNewswire/ – Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of all investors that purchased Oasmia Pharmaceutical AB (NASDAQ: OASM) securities between October 23, 2015 and July 9, 2019 (the “Class Period”). Investors have until September 27 , 2019 to apply to the Court to be …

UPCOMING DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | Globe Newswire | 9/16/2019

September 16, 2019 09:15 ET Source: Schall Law LOS ANGELES, The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Oasmia Pharmaceutical AB (“Oasmia” or “the Company”) (NASDAQ: OASM ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the …

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National General, Mallinckrodt, Oasmia Pharmaceutical, and Aclaris Therapeutics and Encourages Investors to Contact the Firm | Globe Newswire | 9/11/2019

… YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) – Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of National General Holdings Corp. (NASDAQ: NGHC), Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), and Aclaris Therapeutics, Inc. (NASDAQ: ACRS). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the …

OASM CLASS ACTION DEADLINE: Hagens Berman Reminds Investors in Oasmia Pharmaceutical AB (OASM) of Upcoming Lead Plaintiff Deadline | Globe Newswire | 9/11/2019

Class-action law firm urges OASM investors to learn their shareholder rights against Oasmia in filed lawsuit September 10, 2019 20:08 ET Source: Hagens Berman Sobol Shapiro LLP SAN FRANCISCO, Hagens Berman reminds investors in Oasmia Pharmaceutical AB ( NASDAQ: OASM ) of the September 27, 2019 lead plaintiff deadline in a federal securities class action against the company. If you invested in Oasmia securities between October 23, 2015 through July 9 …

Oasmia publishes its annual report and adjusts accounts due to write-downs - auditors do not recommend former board to be granted discharge from liability | Globe Newswire | 9/5/2019

September 05, 2019 09:00 ET Source: Oasmia Pharmaceutical AB multilang-release Oasmia Pharmaceutical AB’s annual report for the fiscal year 2018/2019 is now available on the company’s website www.oasmia.com. Compared to the year-end report, which was published on June 28, the financial statements for the fiscal year have been adjusted as a result of non-cash flow write-downs of SEK 30.9 million. The result for the year and …

Oasmia completes its management team | Globe Newswire | 9/4/2019

September 04, 2019 15:00 ET Source: Oasmia Pharmaceutical AB multilang-release Oasmia has further strengthen its management team with the recruitment of two General Managers to accelerate commercialization of Oasmia. Neil Yman is appointed General Manager for Europe & Russia and Reinhard Koenig is appointed General Manager for USA & Canada. Both have extensive experience of leading positions within global pharmaceutical companies. “The addition of two experienced General Managers will drive the …

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Carbonite and Encourages Investors to Contact the Firm | Globe Newswire | 9/4/2019

September 03, 2019 22:30 ET Source: Bragar Eagel & Squire NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) – Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), Aclaris Therapeutics, Inc. (NYSE: ACRS), and Carbonite, Inc. (NASDAQ: CARB). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information …

OASM LITIGATION DEADLINE REMINDER: Hagens Berman Reminds Investors in Oasmia Pharmaceutical AB (OASM) of September 27, 2019 Lead Plaintiff Deadline | Globe Newswire | 9/4/2019

Class-action law firm urges OASM investors to learn their shareholder rights against Oasmia in filed lawsuit September 03, 2019 20:11 ET Source: Hagens Berman Sobol Shapiro LLP SAN FRANCISCO, Sept. 03, 2019 (GLOBE NEWSWIRE) – Hagens Berman reminds investors in Oasmia Pharmaceutical AB ( NASDAQ: OASM ) of the September 27, 2019 lead plaintiff deadline in a federal securities class action against the company. If you invested in Oasmia securities between October …

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Oasmia Pharmaceutical, Aclaris Therapeutics, Evolent Health, and International Flavors & Fragrances and Encourages Investors to Contact the Firm | Globe Newswire | 8/27/2019

August 27, 2019 08:00 ET Source: Bragar Eagel & Squire NEW YORK, Aug. 27, Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Oasmia Pharmaceutical AB (NASDAQ: OASM), Aclaris Therapeutics, Inc. (NYSE: ACRS), Evolent Health, Inc. (NYSE: EVH), and International Flavors & Fragrances, Inc. (NYSE: IFF). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information …

EDIS

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Oasmia Pharmaceutical AB Investors | Business Wire | 8/7/2019

… the upcoming September 27, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM ) investors who purchased securities between October … International S.A. (“Alceco”) and Ardenia Investments Ltd (“Ardenia”) to the Swedish Economic Crime Authority. Alceco and Ardenia are controlled by the former executive chairman, Julian Aleksov, and his former father-in-law, Bo Cederstrand, who …

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Oasmia Pharmaceutical AB | Business Wire | 8/6/2019

… 27, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM ) securities between October 23, 2015 and … International S.A. (“Alceco”) and Ardenia Investments Ltd (“Ardenia”) to the Swedish Economic Crime Authority. Alceco and Ardenia are controlled by the former executive chairman, Julian Aleksov, and his former father-in-law, Bo Cederstrand, who …

Aclaris

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National General, Mallinckrodt, Oasmia Pharmaceutical, and Aclaris Therapeutics and Encourages Investors to Contact the Firm | Globe Newswire | 9/11/2019

September 10, 2019 19:30 ET Source: Bragar Eagel & Squire NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) – Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of National General Holdings Corp. (NASDAQ: NGHC), Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), and Aclaris Therapeutics, Inc. (NASDAQ: ACRS). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff …

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National General, Mallinckrodt, Oasmia Pharmaceutical, and Aclaris Therapeutics and Encourages Investors to Contact the Firm | Globe Newswire | 9/11/2019

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of National General Holdings Corp. (NASDAQ: NGHC), Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), and Aclaris Therapeutics, Inc. (NASDAQ: ACRS). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. National General Holdings Corp …

Aclaris Therapeutics

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National General, Mallinckrodt, Oasmia Pharmaceutical, and Aclaris Therapeutics and Encourages Investors to Contact the Firm | Globe Newswire | 9/11/2019

September 10, 2019 19:30 ET Source: Bragar Eagel & Squire NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) – Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of National General Holdings Corp. (NASDAQ: NGHC), Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), and Aclaris Therapeutics, Inc. (NASDAQ: ACRS). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff …

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National General, Mallinckrodt, Oasmia Pharmaceutical, and Aclaris Therapeutics and Encourages Investors to Contact the Firm | Globe Newswire | 9/11/2019

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of National General Holdings Corp. (NASDAQ: NGHC), Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), and Aclaris Therapeutics, Inc. (NASDAQ: ACRS). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. National General Holdings Corp …

Peretz Bronstein

DEADLINE ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action and Lead Plaintiff Deadline: September 27, 2019 | Globe Newswire | 9/27/2019

… 2019 (GLOBE NEWSWIRE) – Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM) and certain of its officers, on … visit the firm’s site: www.bgandg.com/oasm or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Oasmia you …

Yael Hurwitz

DEADLINE ALERT - Oasmia Pharmaceutical AB (OASM) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action and Lead Plaintiff Deadline: September 27, 2019 | Globe Newswire | 9/27/2019

… 2019 (GLOBE NEWSWIRE) – Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM) and certain of its officers, on … may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Oasmia you have until September 27, 2019 to request that …

Julian Aleksov

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2019 – Company Announcement - FT.com | Financial Times | 9/26/2019

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2019 EVENTS IN FIRST QUARTER Oasmia presented results from two clinical studies of Docecal in patients with metastatic breast cancer The Board of Directors appointed a special examiner to give all shareholders basis for decision regarding discharge from liability before the AGM Oasmia has found questionable transactions between Oasmia and companies controlled by former chairman Julian Aleksov

Lesley Portnoy

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Oasmia Pharmaceutical AB | Globe Newswire | 9/23/2019

Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM ) investors who purchased securities between October 23, 2015 and July 9, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Howard G. Smith

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Oasmia Pharmaceutical AB | Globe Newswire | 9/20/2019

September 20, 2019 11:00 ET Source: Law Offices of Howard G. Smith BENSALEM, Pa., Sept. 20, Law Offices of Howard G. Smith reminds investors of the upcoming September 27, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM ) securities between October 23, 2015 and July 9, 2019 , inclusive (the “Class Period …

Brian Schall

7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | Globe Newswire | 9/20/2019

… NEWSWIRE) – The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Oasmia Pharmaceutical AB (“Oasmia” or “the Company”) (NASDAQ: OASM ) for violations of §§10(b) and … click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of …

Melissa Fortunato

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Oasmia Pharmaceutical AB (NASDAQ: OASM) and Encourages Oasmia Investors to Contact the Firm | PR Newswire | 9/19/2019

… in the United States District Court for the Eastern District of New York on behalf of all investors that purchased Oasmia Pharmaceutical AB (NASDAQ: OASM ) securities between October 23, 2015 and July 9, 2019 (the … with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected] , or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation …

Bragar Eagel

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Oasmia Pharmaceutical AB (NASDAQ: OASM) and Encourages Oasmia Investors to Contact the Firm | PR Newswire | 9/19/2019

NEW YORK Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of all investors that purchased Oasmia Pharmaceutical AB (NASDAQ: OASM ) securities between October 23, 2015 and July 9, 2019 (the “Class Period”). Investors have until September 27 , 2019 to apply to the Court to be appointed as lead plaintiff …

Brandon Walker

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Oasmia Pharmaceutical AB (NASDAQ: OASM) and Encourages Oasmia Investors to Contact the Firm | PR Newswire | 9/19/2019

… in the United States District Court for the Eastern District of New York on behalf of all investors that purchased Oasmia Pharmaceutical AB (NASDAQ: OASM ) securities between October 23, 2015 and July 9, 2019 (the … rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected] , or telephone at (212) 355-4648, or by filling out this contact form. There is no …

Reed Kathrein

OASM CLASS ACTION DEADLINE: Hagens Berman Reminds Investors in Oasmia Pharmaceutical AB (OASM) of Upcoming Lead Plaintiff Deadline | Globe Newswire | 9/11/2019

… filed lawsuit September 10, 2019 20:08 ET Source: Hagens Berman Sobol Shapiro LLP SAN FRANCISCO, Hagens Berman reminds investors in Oasmia Pharmaceutical AB ( NASDAQ: OASM ) of the September 27, 2019 lead plaintiff deadline in a … investors about improper related-party transactions,” said Hagens Berman partner Reed Kathrein. Whistleblowers: Persons with non-public information regarding Oasmia should consider their options to help in the investigation or take advantage of the SEC …

Phillip Kim

ROSEN, A TOP RANKED LAW FIRM, Reminds Oasmia Pharmaceutical AB Investors of Important Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact the Firm – OASM | Globe Newswire | 8/10/2019

Oasmia Pharmaceutical AB (NASDAQ: OASM) from October 23, 2015 through July 9, 2019, inclusive (the “Class Period”) of the important September 27, 2019 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Oasmia investors under the federal securities laws. To join the Oasmia class action, go to http://www.rosenlegal.com/cases-register-1620.html or call Phillip Kim, Esq. toll-free …

Laurence Rosen

ROSEN, A HIGHLY RANKED LAW FIRM, Reminds Oasmia Pharmaceutical AB Investors of Important Deadline in Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $100K to Contact the Firm – OASM | Business Wire | 8/3/2019

NEW YORK- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Oasmia Pharmaceutical AB (NASDAQ: OASM) from October 23, 2015 through July 9, 2019, inclusive (the “Class Period”) of … Attorney advertising. Prior results do not guarantee future outcomes. Contacts Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34 th Floor New York, NY 10016 Tel: (212) 686-1060 Toll …

Robert S. Willoughby

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Oasmia Pharmaceutical AB - OASM | Globe Newswire | 8/3/2019

Pomerantz LLP is investigating claims on behalf of investors of Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The investigation concerns whether Oasmia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On July 9 …